Your Article Summary
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometric in myelodysplastic syndromes
Haematologica, 06/26/09
Van De Loosdrecht AA et al. - The group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies.
Related Articles
Prognostic molecular markers in myelodysplastic syndromes
Expert Review of Hematology, 10/22/09
Relevance Score: 68%
Hematopoiesis-related microRNA expression in myelodysplastic syndromes
Leukemia and Lymphoma, 11/06/09
Relevance Score: 67%
Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome
International Journal of Laboratory Hematology, 10/28/09
Relevance Score: 66%
Accelerated cellular senescence in myelodysplastic syndrome
Experimental Hematology, 10/22/09
Relevance Score: 66%
Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression
Blood, 10/09/09
Relevance Score: 66%
Today in Diagnostics/Radiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Systematic Review: Comparative Effectiveness of Core-Needle and Open Surgical Biopsy to Diagnose Breast Lesions
Annals of Internal Medicine, 12/15/09
Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer
Archives of Internal Medicine, 12/15/09
Life expectancy of screen-detected invasive breast cancer patients compared with women invited to the Nijmegen screening program
Cancer, 12/15/09
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells
European Journal of Haematology, 12/11/09
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome
Blood, 12/10/09
Solitary Plasmacytoma
American Journal of Clinical Oncology, 12/08/09

See Latest Articles